HER2 testing in gastric cancer: a practical approach (Q28256814)

6

object named as

Frédérique Penault-Llorca

0 references

Marc van de Vijver

7

object named as

Marc van de Vijver

0 references

Giuseppe Viale

8

object named as

Giuseppe Viale

0 references

author name string

Josef Rüschoff

1

0 references

Wedad Hanna

2

0 references

Michael Bilous

3

0 references

Manfred Hofmann

4

0 references

Robert Y Osamura

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

5

0 references

language of work or name

English

0 references

publication date

May 2012

0 references

published in

Modern Pathology

0 references

volume

25

0 references

issue

5

0 references

page(s)

637-50

0 references

cites work

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.198

7 January 2021

Current perspectives on HER2 testing: a review of national testing guidelines

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.198

7 January 2021

HER-2 amplification is highly homogenous in gastric cancer.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.198

7 January 2021

Standardization of HER2 testing: results of an international proficiency-testing ring study.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.198

7 January 2021

Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.198

7 January 2021

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.198

7 January 2021

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.198

7 January 2021

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.198

7 January 2021

Epidemiology of gastric cancer in Japan

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.198

7 January 2021

Gastric cancer screening and subsequent risk of gastric cancer: a large-scale population-based cohort study, with a 13-year follow-up in Japan

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.198

7 January 2021

Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.198

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.198

7 January 2021

Overexpression of HER2/neu in solid tumours: an immunohistochemical survey

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.198

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.198

7 January 2021

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.198

7 January 2021

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.198

7 January 2021

HER-2/neu amplification is an independent prognostic factor in gastric cancer.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.198

7 January 2021

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.198

7 January 2021

Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.198

7 January 2021

[Her2 testing in gastric cancer. What is different in comparison to breast cancer?].

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.198

7 January 2021

HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.198

7 January 2021

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.198

7 January 2021

Retrieved endogenous biotin: a novel marker and a potential pitfall in diagnostic immunohistochemistry

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.198

7 January 2021

Image analysis as an adjunct to manual HER-2 immunohistochemical review: a diagnostic tool to standardize interpretation

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.198

7 January 2021

10.1038/MODPATHOL.2011.198

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

Dimensions Publication ID

303763

1027273989

0 references

303763

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference